The largest opportunities for organ regeneration lie in diseases/disorders of the bone marrow, kidneys, liver, pancreas, and small intestine. Market segments covered by this report include bioartificial kidneys and livers/liver regeneration products, bone marrow regeneration products, pancreas regeneration products, and small intestine replacement products. Various tissue engineering technologies including genes, scaffolds, stem cells, and xenotransplants are being researched for applications in organ regeneration.
This new report also provides a clinical overview of selected diseases/disorders that are amenable to treatment with tissue-engineered and cell transplantation products and includes the most up-to-date incidence and prevalence figures.
This report is the fifth in a series of six Medtech Insight reports covering U.S. tissue engineering and cell transplantation markets. The final report in this series will provide an analysis of the U.S. market for tissue-engineered skin replacement and skin substitute products.
EXECUTIVE SUMMARY i. Clinical Applications for Organ Regeneration a. Bone Marrow Disease b. Diabetes c. Intestinal Disorders d. Kidney Disease e. Liver Disease ii. Tissue Engineering Technologies a. Biomaterials b. Cell Culture Technology c. Stem Cell Technology d. Immunoisolation Technology iii. Technologies Under Development for Organ Regeneration a. Bone Marrow Regeneration Technologies b. Intestine Regeneration Technologies c. Kidney Regeneration Technologies d. Liver Regeneration Technologies e. Pancreas Regeneration Technologies f. Bioartificial Organ Technologies iv. Market Analysis v. Methodology Exhibit ES-1: Organ Regeneration Products, Potential Market Forecast, 2009 and 2019 1. CLINICAL OVERVIEW OF TISSUE ENGINEERING APPLICATIONS FOR ORGAN REGENERATION 1.1 Disease Incidence 1.1.1 Bone Marrow Disease 18.104.22.168 Aplastic Anemia 22.214.171.124 Leukemia and Lymphoma 1.1.2 Diabetes 1.1.3 Intestinal Disorders 126.96.36.199 Intestinal Pseudo-Obstruction 188.8.131.52 Microvillus Inclusion Disease 184.108.40.206 Short Bowel Syndrome 1.1.4 Kidney Disease 1.1.5 Liver Disease 1.2 Existing Therapies 1.2.1 Ex Vivo Systems 220.127.116.11 Kidney Dialysis Systems 1.2.2 Organ Transplantation 18.104.22.168 Bone Marrow Transplantation 22.214.171.124 Kidney Transplantation 126.96.36.199 Liver Transplantation 188.8.131.52.1 Split Cadaveric Livers 184.108.40.206.2 Liver Segments from Living Donors 220.127.116.11 Pancreas Transplantation 18.104.22.168 Intestinal Transplantation Exhibit 1-1: Incidence and Prevalence of Major Organ Diseases/Disorders Exhibit 1-2: Organ Transplantation, by Type, Procedure Volumes, and Waiting List Exhibit 1-3: Average Estimated First-Year Billed Charges, Per Transplant 2. TISSUE ENGINEERING AND ORGAN REGENERATION TECHNOLOGIES 2.1 Biomaterials 2.1.1 Synthetic Biomaterials 2.1.2 Biologically Derived Biomaterials 22.214.171.124 Collagen 126.96.36.199 Xenogeneic Tissue 2.1.3 Hybrid Biomaterials 2.1.4 Genetically Engineered Biomaterials 188.8.131.52 Deoxyribonucleic Acid Transfection Vectors 184.108.40.206 Genetically Manipulated Cells 220.127.116.11 Three-Dimensional Polymer Technology 18.104.22.168 Transgenics 22.214.171.124 Fibroblasts 126.96.36.199 Immortalized Neural Stem Cells 188.8.131.52 Gene-Activated Matrices 2.1.5 Scaffolds 2.1.6 Vascular Grafts 2.2 Cell Culture Technology 2.2.1 Bioreactors 184.108.40.206 Flatbed Perfusion Systems 220.127.116.11 Hollow Fiber Bioreactor Systems 18.104.22.168 Cell Suspension Systems 22.214.171.124 Disposable Bioreactors 2.3 Stem Cell Technology 2.3.1 Cell Extraction and Expansion 2.3.2 Bioreactors 2.4 Immunoisolation Technology 2.4.1 Chimeric Immunity 2.4.2 Cell Encapsulation Technology Exhibit 2-1: 2010, Selected Synthetic Biomaterials Used in Tissue Engineering Exhibit 2-2: 2010, Selected Natural Biomaterials Used in Tissue Engineering Exhibit 2-3: 2010, Selected Current and Emerging Cell Extraction, Expansion, and Separation Products and Technologies 3. TISSUE ENGINEERING AND CELL TRANSPLANTATION: U.S. MARKETS FOR ORGAN REGENERATION PRODUCTS 3.1 Emerging Technologies and Products 3.1.1 Genes 3.1.2 Scaffolds 3.1.3 Stem Cells 3.1.4 Xenotransplants 3.1.5 Bone Marrow 126.96.36.199 Gamida Cell 188.8.131.52 Osiris Therapeutics 184.108.40.206 SituGen 220.127.116.11 University of Texas M.D. Anderson Cancer Center and the ViaCord Research Institute/ViaCord/PerkinElmer 3.1.6 Intestine 3.1.7 Kidney 18.104.22.168 Tengion 3.1.8 Liver 22.214.171.124 Cytonet 126.96.36.199 StemCells 188.8.131.52 Vesta Therapeutics 3.1.9 Pancreas 184.108.40.206 BioTime 220.127.116.11 Cerco Medical 18.104.22.168 Geron 22.214.171.124 Juvenile Diabetes Research Foundation 126.96.36.199 Osiris Therapeutics 188.8.131.52 ViaCyte 184.108.40.206 StemCells 220.127.116.11 TheraCyte 18.104.22.168 Transition Therapeutics 22.214.171.124 ViaCord/PerkinElmer 126.96.36.199 Vitro Biopharma/Vitro Diagnostics 3.2 Artificial Organ Technologies 3.2.1 Bioartificial Kidney 3.2.2 Bioartificial Liver 188.8.131.52 Excorp Medical 184.108.40.206 Gambro 220.127.116.11 HepaLife Technologies 18.104.22.168 Hep-Art Medical Devices 22.214.171.124 Hybrid Organ 126.96.36.199 Vital Therapies 188.8.131.52 Xenogenics/MultiCell Technologies 3.2.3 Artificial Pancreas 184.108.40.206 Juvenile Diabetes Research Foundation 220.127.116.11 Medtronic 3.3 Market Analysis 3.3.1 Market Drivers 3.3.2 Market Limiters 3.4 Competitors Exhibit 3-1: 2010, Selected Emerging Treatment Products for Liver Failure Exhibit 3-2: 2010, Selected Emerging Treatment Products for Pancreatic Failure Exhibit 3-3: 2010, Selected Bioartificial and Artificial Organ Products Exhibit 3-4: Medtronic's STAR 3 Study Results Exhibit 3-5: Organ Regeneration Products, Potential Market Forecast, 2009 and 2019 Exhibit 3-6: Organ Regeneration Technologies, by Indication, 2009 and 2019 4. COMPANY PROFILES 4.1 BioTime, Inc. 4.2 Cerco Medical LLC 4.3 Cytonet GmbH & Co. KG 4.4 Geron Corporation 4.5 Osiris Therapeutics, Inc. 4.6 PerkinElmer, Inc. 4.7 StemCells, Inc. 4.8 Tengion, Inc. 4.9 Vesta Therapeutics, Inc. 4.10 ViaCyte, Inc. APPENDIX: COMPANY LISTING